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Abstract
Background: Antineutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitides have a variety of
presentations, but cardiac valvular involvement is rarely diagnosed and its management is not established.
Case presentation: We report the case of a 44 year old man who presented with an ANCA-associated systemic
vasculitis and aortic regurgitation of unusual mechanism. Transthoracic and transesophageal echocardiography
disclosed septal hypertrophy preventing a complete closure of the aortic valve and thus responsible for a massive
aortic regurgitation. After 4 months of immunosuppressive therapy, the valve lesion did not subside and the patient
had to undergo aortic valve replacement. This report also reviews the 20 cases of systemic ANCA-associated vasculitis
with endocardial valvular involvement previously reported in the English language medical literature.
Conclusions: Valvular involvement in ANCA-associated systemic vasculitides is rarely reported. Most of these
lesions are due to Wegener’s granulomatosis and half are present when the diagnosis of vasculitis is made. The
valvular lesion is usually isolated, aortic regurgitation being the most frequent type, and often requires valve
replacement in the months that follow it’s discovery.
Background
Antineutrophil cytoplasmic antibodies (ANCA)-associated
systemic vasculitides are a group of small vessel vasculitic
syndromes including Wegener’s granulomatosis, micro-
scopic polyangiitis and Churg Strauss syndrome. These dis-
eases share a common pathology with focal necrotizing
lesions that affect different vessels and organs. Wegener’s
granulomatosis and Churg Strauss syndrome have addi-
tional granulomatous lesions. They have a variety of presen-
tations, but cardiac valvular involvement is rarely reported.
In this report we describe the case of a patient with an
ANCA associated systemic vasculitis who presented with
aortic regurgitation of unusual mechanism requiring
surgical replacement.
Case report
The patient was a 44-year-old man from Bangladesh
who immigrated to France twenty years ago and worked
in several dusty embroidery workshops. Eight months
prior to his admission in our hospital, he developed
right chronic headaches resisting usual painkillers with
right hypoacusia and tinnitus. The right ear examination
was consistent with chronic otitis media. A sinus CT
scan showed pansinusitis predominating on the right
side with right mastoiditis and otitis media. A cerebral
MRI showed pachymeningitis of the cerebellopontine
angle. Right myringotomy yielded culture-negative drai-
nage. The patient underwent several unsuccessful anti-
biotic treatments.
Eight months after the onset of the disease, the patient
was referred to our ward, complaining, in addition to
the other symptoms, of signs of severe intracranial
hypertension (persistant right headaches and vomiting),
significant weight loss, and a change in his voice. Otor-
hinological examination showed an unchanged right ear,
a paralysis of the left vocal cord responsible for the dys-
phonia, an abolition of the gag reflex, and a palatal
paralysis. The blood pressure was 140/65 mmHg, the
heart rate of 75 bpm and the general examination was
normal aside from a three out of four diastolic murmur
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any medium, provided the original work is properly cited.of aortic regurgitation, without any other cardiac signs
and a normal electrocardiogram.
An abdominal CT-scan showed a focal thickening of
the aortic arch and an identical thickening of the super-
ior mesenteric vein, interpreted as focal aortic and
mesenteric vasculitis. A mesenteric panniculitis was also
apparent. Laboratory studies included the following
values: C-reactive protein 35 mg/l, serum urea nitrogen
4.6 mM/l, creatinine 86 mcM/l, total leukocyte count
10.3 × 10^9/l, polyclonal hypergammaglobulinemia,
negative antiphospholipid antibodies, positive antineu-
trophil cytoplasmic antibodies (ANCA) with positive
antimyeloperoxidase antibodies and negative antiprotei-
nase 3 antibodies. The cerebrospinal fluid contained 60
cells per mm3 with 28% lymphocytes and 1.11 g/l of
protein; the bacterial, fungal and mycobacterial cultures
were negative. The cerebral MRI performed on admis-
sion was unchanged. Inferior nasal concha biopsies
showed nonspecific inflammation; temporal artery biop-
sies were normal. Transthoracic and transesophageal
echocardiography revealed septal hypertrophy leading to
a restriction of aortic valvular closure and thus to mas-
sive aortic regurgitation (Figure 1).
The presumptive diagnosis was ANCA-associated sys-
temic vasculitis, most probably Wegener’s granulomato-
sis, with aortic valvular involvement. Treatment with
prednisone (1 mg/kg) and intravenous cyclophospha-
mide (700 mg/m2 every two weeks during one month
then every four weeks) was started. With this immuno-
suppressive therapy the palatal paralysis subsided, the
headaches lessened and the patient, slowly regaining
weight and energy, was able to return home.
Four months after the beginning of treatment there was
an absence of echocardiographic improvement of the sep-
tal hypertrophy and aortic regurgitation and the patient
had developed congestive heart failure, so the decision was
made to perform an aortic Bicarbon™valve replacement.
Upon inspection, the aorta wall and the aortic valve leaf-
lets appeared diffusely thickened. There was a focal thick-
ening of the interventricular septum covered with fibrous
tissue. Fibrous tissue was also found on the aortic ring and
on the large mitral leaflet. No vegetations were seen. At
the end of surgery the patient was in persistent complete
heart block requiring a pacemaker implantation.
The microscopic examination of the septum showed
chronic remodelling with fibrous and hyaline tissue, and
Figure 1 Transesophageal echocardiography showing septal hypertrophy (white arrows) and lack of central coaptation of aortic valve
(yellow arrows), resulting in massive aortic regurgitation. Ao = aorta. LA = left atrium. LV = left ventricle.
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as well as a local fragmentation of the elastic fibers was
found in the intima and media of the aortic wall. No
inflammatory infiltrate nor granuloma were seen in the
aortic specimens.
Two years after surgery, the patient is doing well on
azathioprine (see Table 1).
Discussion
In this patient, the diagnosis of ANCA-associated sys-
temic vasculitis, most probably Wegener’s granulomato-
sis, was based on the association of pansinusitis, otitis,
mastoiditis, chronic lymphocytic meningitis, aortitis and
positive ANCA. This diagnosis was assessed at the
National Referral Center for Rare Systemic and Autoim-
mune Diseases, Necrotizing Vasculitides, and Systemic
Sclerosis (Hôpital Cochin, Assistance Publique-Hôpitaux
de Paris, Université Paris-Descartes, Paris). Although
Pr3-ANCA, found in 70 to 90% of patients with Wege-
ner’s granulomatosis, is often considered to be a sero-
marker of this disease, MPO-ANCA has been reported
to be predominant in Asian patients [1]. This could
explain the positive p-ANCA and negative c-ANCA in
this patient who is from Bangladesh. The very unusual
and unique feature in this patient was the particular
mechanism of aortic valve involvement that required a
valve replacement.
Using a Pubmed search we looked for reported cases
of ANCA-associated systemic vasculitis with a valvular
involvement, using the keywords “valve”, “cardiac”,
“heart”, “endocarditis”, “mitral”, “aortic”, “tricuspid”,
“pulmonary”, “ANCA”, “antineutrophil cytoplasmic anti-
bodies”, “Wegener’s granulomatosis”, “microscopic poly-
angiitis” and “Churg Strauss” in different combinations.
We completed this search by cross-referencing pub-
lished articles. We thus selected 19 articles in English
reporting 20 cases consistent with a systemic ANCA-
associated vasculitis with endocardial valvular involve-
ment, i.e. valvular lesions for which infective endocardi-
tis had been excluded and no other aetiology found
[2-20].
The general characteristics of the patients and of their
vasculitides are reviewed in Table 2. Their average age
tends to be younger than that of the other patients pre-
senting an ANCA-associated-vasculitis (40 versus 47
years old [21]) and the male predominance is greater
(80% versus 53% [21]). One case excepted [19], all
reported cases were diagnosed as Wegener’s granuloma-
tosis and presented with at least one of the three most
common involvements, i.e. renal, pulmonary and otolar-
yngological. Eye, skin or joint involvement was present
in about half the cases. Only 6 patients out of 20 experi-
enced another cardiac lesion, such as pericardial effusion
or adhesions [6,10,15], conduction disorders [4,9,10] and
coronary artery stenosis [12].
Table 3 details the characteristics of the valvular
lesions in the 20 different cases. The most commonly
encountered disorder is aortic regurgitation
[4-11,13,14,19,20]. Seven cases of mitral regurgitation
[3,7,11-13,15,20], and one of aortic stenosis [2] were
also reported along with two cases of valvular vegeta-
tions [16,17], two of a mass involving a mitral leaflet
Table 1 Symptoms, severity score index and main lab and imagery results of the patient described in the case report
November 2006 - Persisting facial pain, right chronic headaches resisting usual pain killers
- Cerebral CT-scan: pansinusitis
March 2007 - Same symptoms + right hypoacusia and tinnitus
- Cerebral CT-scan: pansinusitis predominating on the right side with right mastoiditis and otitis media
- Cerebral MRI: pachymeningitis of the cerebellopontine angle
June 2007 When hospitalized:
- Violent headaches and vomiting: severe intracranial hypertension
- Significant weight loss (- 10 kg)
- Right otitis media
- Paralysis of the left vocal cord (dysphonia), abolition of the gag reflex, and palatal paralysis
- Cerebral MRI: unchanged
- Spinal tap: Aseptic meningitis
- Discovery of the aortic regurgitation
- Abdominal CT-scan: focal aortic and mesenteric vasculitis and mesenteric panniculitis
- Elevated C-reactive protein and leukocyte count
- Polyclonal hypergammaglobulinemia
- pANCA+; anti-MPO +; anti Pr3 -
- BVAS = 23
June 2009 BVAS = 2
BVAS: Birmingham Vasculitis Activity Score.
Lacoste et al. BMC Musculoskeletal Disorders 2011, 12:50
http://www.biomedcentral.com/1471-2474/12/50
Page 3 of 6responsible for mild mitral stenosis and moderate mitral
regurgitation [3,13], and one of multiple atrial masses
without valvular insufficiency or stenosis [18]. Six
patients had polyvalvular involvement [3,7,11,13,16,20].
Several mechanisms responsible for these valvular
lesions have been reported: vegetations [2,8,16,17,19],
leaflet thickening [4,6,9,13,20], valvular perforation
[6,14] and unique or multiple endocardial masses
[3,9,12,13,18].
Half the valvular lesions were present at initial presen-
tation and when the diagnosis of vasculitis was made
[2,6,7,9,12,14,16-18]. In six of the ten remaining cases,
the valvular disease occurred while the patient was on
immunosuppressant drugs [5,8,10,11,13,19]. In two of
these five cases, the onset was less than a week after the
treatment was initiated suggesting that the pathological
process was already taking place when the drugs were
started [8,19]. In only four cases valvular disease began
Table 2 General characteristics of patients with systemic vasculitides and valvular involvement
Reference Sex Age ANCA Vasculitis
Classification
Kidney ENT Organ
Lungs
Involvement
Eyes
Skin Joints Non-valvular
cardiac
lesion
Stöllberger [19] M 56 ANCA -, anti-PR3 + Unknown Yes - - - Yes Yes -
Levine [15] M 28 - Wegener’s
granulomatosis
Yes Yes Yes - - - Yes
Davenport [6] M 19 c-ANCA +, anti-PR3
+
Wegener’s
granulomatosis
Yes Yes Yes Yes Yes Yes -
M 53 c-ANCA +, anti-PR3
+
Wegener’s
granulomatosis
Yes - - - - - Yes
Grant [10] M 32 c-ANCA + Wegener’s
granulomatosis
- Yes - Yes Yes Yes Yes
Goodfield [9] M 25 c-ANCA + Wegener’s
granulomatosis
- Yes Yes - - - Yes
Bruno [4] F 63 ANCA + Wegener’s
granulomatosis
- Yes Yes - - - Yes
Herbst [12] F 56 ANCA - Wegener’s
granulomatosis
- - Yes - - Yes Yes
Gerbracht [8] M 20 - Wegener’s
granulomatosis
Yes Yes Yes - - - -
Greidinger [11] M 15 c-ANCA + Wegener’s
granulomatosis
Yes Yes Yes - Yes Yes -
Leff [14] M 17 c-ANCA + Wegener’s
granulomatosis
- Yes Yes - Yes Yes -
Yanda [20] F 77 - Wegener’s
granulomatosis
Yes Yes Yes Yes Yes - -
Dabbagh [5] M 16 - Wegener’s
granulomatosis
Yes Yes Yes Yes - - -
Fox [7] M 20 ANCA + Wegener’s
granulomatosis
Yes Yes Yes Yes Yes Yes -
Anthony [2] M 48 c-ANCA +, anti-PR3
+
Wegener’s
granulomatosis
- Yes Yes - Yes Yes -
Paik [17] M 48 c-ANCA + Wegener’s
granulomatosis
- Yes Yes - - - -
Mishell [16] M 65 ANCA +, anti-PR3 + Wegener’s
granulomatosis
Yes - Yes Yes Yes - -
Ramakrishnan
[18]
F 44 c-ANCA + Wegener’s
granulomatosis
Yes - Yes - - - -
Attaran [3] M 52 - Wegener’s
granulomatosis
- Yes - - - - -
Koyalakonda [13] M 52 - Wegener’s
granulomatosis
- Yes - Yes - - -
Present report M 44 p-ANCA +, anti-PR3 - Wegener’s
granulomatosis
- Yes - - - - -
ANCA: antineutrophil cytoplasmic antibodies; ENT: ear, nose and/or throat involvement; PR3: proteinase-3.
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[3,4,10,20].
A valve replacement was required in most cases
[3,4,6,7,9,10,12,13,19,20]. In only two cases did immuno-
suppressive therapy allow a complete resolution of the
valvular lesions [8,9]; and in one of these [9] the patient
had nonetheless to undergo an aortic valve replacement
because of secondary left ventricular dilatation and a
shrunken leaflet.
The pathological findings were nonspecific in almost
all cases; i.e. showing inflammation and/or scarring
without abscess, giant cells, vasculitis, or granuloma. In
Table 3 Valvular lesion characteristics in patients with systemic vasculitides
Reference Valve lesion onset Valve
lesion
Mechanism of valvular
disease
Valvular
treatment
Outcome Valve
histology
Stöllberger
[19]
After 3 days steroïds AR Vegetation - AVR Non
specific
Levine [15] After 6 weeks of ENT
signs no IST
MR ? - Died of heart failure -
Davenport [6] At initial
presentation
AR Leaflet perforation and
tissue disruption
1 year IST AVR Non
specific
At initial
presentation
AR Thickened leaflets IST Worse, awaiting AVR -
Grant [10] After 1 year of CYC AR Dilation of ascending aorta 20 Mo IST AVR Non
specific
Goodfield [9] At initial
presentation
AR Thickened leaflets and mass
obstructing the left ventricular
outflow tract
6 weeks
IST
Thickening & mass disappeared. AVR
because of LV dilatation & shrunken
Ao leaflet
Non
specific
Bruno [4] 3 years after illness
onset, no IST
AR Thickened, rigid and retracted
leaflets
_ AVR Specific
Herbst [12] At initial
presentation
MR Mass involving a leaflet MVR & AVR Specific
Gerbracht [8] After 5 days CYC AR Vegetation IST Complete resolution -
Greidinger
[11]
After 3 weeks CYC AR ? IST Lesion unchanged -
MR ? IST Lesion unchanged -
Leff [14] At initial
presentation
AR Perforation of 2 leaflets 1 year IST Ao valve repair: homograft -
Yanda [20] 1 year after initial
presentation,
no IST
AR Thickened leaflet - AVR Non
specific
MR Thickened leaflet IST ? -
Dabbagh [5] After 3 weeks CYC AR ? IST ? -
Fox [7] At initial
presentation
AR Prolapsing Ao leaflets and
discrete Ao leaflet deficiency
5 Mo IST AVR Non
specific
MR ? IST ? -
Anthony [2] At initial
presentation
AS Vegetation 3 Mo IST Lesion unchanged -
Paik [17] At initial
presentation
Ao
vegetations
Vegetation IST ?
Mishell [16] At initial
presentation
Ao and M
vegetations
Vegetations IST Died Non
specific
Ramakrishnan
[18]
At initial
presentation
M masses Multiple masses in atriums and
on MP
Few days
IST
Died -
Attaran [3] 30 years after illness
onset, IST?
Ao and M
mass, MR,
MS
Mass involving an Ao and an M
leaflet
IST MVR & AVR Non
specific
Koyalakonda
[13]
Not at initial
presentation and
under treatment
MS & MR
AR
M mass involving leaflet
Thickened Ao valve
IST
IST
Mass unchanged: MVR
AR progressed: AVR
Non
specific
Present report At initial
presentation
AR Septal thickening: incomplete
closure of Ao valve, thickened
leaflets
4 Mo IST AVR Non
specific
?: Unknown; AR: aortic regurgitation; Ao: aortic; AS: aortic stenosis; AVR: aortic valve replacement; CYC: cyclophosphamide; IST: immunosuppressive therapy; LV:
left ventricular; M: mitral; Mo: months; MP: mitral prothesis; MR: mitral regurgitation; MS: mitral stenosis; MVR: mitral valve replacement.
Lacoste et al. BMC Musculoskeletal Disorders 2011, 12:50
http://www.biomedcentral.com/1471-2474/12/50
Page 5 of 6two cases, granuloma, necrosis and/or micro abscess
were described in the valvular tissue [4,12].
To conclude, although it might be underdiagnosed
due to the lack of patent clinical signs and the absence
of systematic screening, valvular involvement in ANCA-
associated systemic vasculitides is rarely reported. Most
of these valvular lesions are due to Wegener’sg r a n u l o -
matosis and half are present when the diagnosis of vas-
culitis is made. The valvular lesion is usually unique,
aortic regurgitation being the most frequent type, and
often requires valve replacement in the months that fol-
low its discovery.
Consent
written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images.
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